Obstetric Thromboprophylaxis: The Swedish Guidelines

Table 2

Risk points, each corresponding to a five-fold increased risk, are added, yielding a risk score.

1 point	2 points	3 points	>4 points^5	Very high risk^6
Heterozygote FV Leiden	Prot S deficiency	Homo FV Leiden	Prior VTE	Mechanical heart prosthesis
Heterozygote FII mut	Prot C deficiency	Homo FII mut	APS without VTE^7	Chronic warfarin prophylaxis
Overweight^1	Immobilization^4			Antithrombin deficiency
Cesarean Section				Recurrent VTE
Heredity for VTE^2				APS with VTE^7
Age >40 years
Preeclampsia
Hyperhomocysteinemia^3
Abruptio placenta
Inflammatory bowel disease
Other major riskfactor

Homo: Homozygote, mut: mutation, VTE: venous thrombembolism.
APS: Antiphospholipidsyndrome, Prot: protein, FV: faktor V, FII: factor II (prothrombin).
¹Overweight = (BMI >28 in early pregnancy).
²VTE in first-degree relative <60 years of age.
³Homocysteine >8 μmol/L in pregnancy.
⁴During cast treatment for fracture or strict bed rest short-term thromboprophylaxis is recommended.
⁵Women with prior VTE or APS without VTE have risk score 4 independent of other risk factors.
⁶Women in this group are classified as “very high risk” and are not scored.
⁷Women with APS are recommended low dose (75 mg) acetylsalicylic acid in addition to LMWH.
The risk score is formed by adding each point to a score between 0 and maximum 4 (for >4 points).